Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OM-85-IN in Healthy Volunteers and Mild Allergic Asthma
NCT06486662Phase 1Completed
- Sponsor
- OM Pharma
- Start
- Jun 2024
- Primary completion
- Feb 2025
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of OM-85 in allergic asthma (8 cohorts), sponsored by OM Pharma. Primary endpoint: Treatment-Emergent Adverse Events at 28 days. Started Jun 2024; status: completed.
02
Drugs
OM-85
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT06486662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06486662.